Developing new medicines is one of humanity’s hardest and most consequential challenges— and a defining opportunity for AI.
AI doesn’t need to discover drugs on its own to deliver enormous value today. Agents built around scientists’ existing data, tools, and workflows can dramatically expand the pace and scale of their work.
As AI transforms what scientists can explore, their judgment matters more than ever. Scientists set direction, shape hypotheses, and turn evidence into next steps. AI frees them to pursue those ideas faster, spending less time searching for information or carrying out repetitive work.
Pharmaceutical companies have long built their discoveries on distinctive technologies and hard-won data. Their scientists should be able to multiply the value of those foundations with AI without having to become AI experts themselves.
At Mirror, we leverage our deep expertise in AI, foundational roots in drug discovery, and state-of-the-art agentic platform to build and deploy custom systems for pharmaceutical companies. We work as partners to pharma founders and their teams, helping turn their visions for AI into capabilities that advance their medicines.
Founder & CEO
Kayvon Tabrizi has over a decade of research and industry experience in the pharmaceutical applications of molecular simulation. Before co-founding Mirror, Kayvon developed the drug discovery platform at D.E. Shaw Research, a leading institution for simulation-driven drug discovery, where he worked on advanced forcefields and free energy methods as a scientific research specialist.
Kayvon leads a world-class team of scientists and engineers. Join us
Investment
And more, including Factorial Capital and angels from Hugging Face, Cursor, and other leaders in AI and biotechnology.
